NOVARTIS AG-REG (NVSEF:OTCMKTS)
$148.78 -4.87 (-3.1695%)
Analysed NOVARTIS AG-REG (NVSEF:OTCMKTS) News Sources
Novartis Buys Myricx Bio in $1.5 Billion Deal
07-07-2026
yahoo.com
Novartis (SWX:NOVN) To Acquire Myricx Bio In $1.5 Billion Oncology Deal
07-07-2026
yahoo.com
3 Cancer Stocks to Watch as Oncology Innovation Accelerates
08-07-2026
yahoo.com
The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
08-07-2026
marketbeat.com
This Analyst Sees 34% Upside For SRPT Stock — Here's Why They Expect A Sustained Rally Next
09-07-2026
stocktwits.com
Systemic Lupus Erythematosus Market at a Turning Point as 6 Late-Stage Emerging Therapies Set to Redefine Treatment Landscape | DelveInsight
09-07-2026
yahoo.com
Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?
09-07-2026
fool.com
Reasons Why Investors Should Consider Betting on PTC Stock Now
10-07-2026
yahoo.com
Chai Discovery Announces Collaboration with Novartis to Advance AI-Driven Antibody Discovery
13-07-2026
yahoo.com
Advancements in CKD Care: How New Therapies from AstraZeneca, Johnson & Johnson, Novartis, Bayer, and Amgen Are Changing the Landscape
14-07-2026
yahoo.com
What is the current price of NOVARTIS AG-REG (NVSEF:OTCMKTS)?
The current price of NOVARTIS AG-REG (NVSEF:OTCMKTS) is $148.78.
NOVARTIS AG-REG (NVSEF:OTCMKTS) absolute price change since previous trading day?
The absolute price change of NOVARTIS AG-REG (NVSEF:OTCMKTS) since the previous trading day is $-4.87.
NOVARTIS AG-REG (NVSEF:OTCMKTS) percentage price change since previous trading day?
The percentage price change of NOVARTIS AG-REG (NVSEF:OTCMKTS) since the previous trading day is -3.1695%.
What is the most recent average sentiment score for NOVARTIS AG-REG (NVSEF:OTCMKTS)?
The most recent average sentiment score for NOVARTIS AG-REG (NVSEF:OTCMKTS) is 69 out of 100.
What is the most recent average sentiment for NOVARTIS AG-REG (NVSEF:OTCMKTS)?
The most recent sentiment for NOVARTIS AG-REG (NVSEF:OTCMKTS) is .
SEC-8K** Filing Available For NOVARTIS AG-REG (NVSEF:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.